ClinicalTrials.Veeva

Menu

An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

W

Wei Hao

Status and phase

Terminated
Phase 4

Conditions

Methamphetamine Dependence

Treatments

Drug: Aripiprazole
Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01813656
100000-068942

Details and patient eligibility

About

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics,but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Full description

Methods:A Multiple-Center, Randomized, Double-Blind.

Enrollment

10 patients

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.
  2. Must sign a Information consent form.
  3. Required to provide detailed address and phone number

Exclusion criteria

  1. Serious organic disease.
  2. Suicide ideation or hurt others.
  3. Taking antipsychotic within two weeks before.
  4. drug allergy to Risperidone or Aripiprazole.
  5. pregnancy and breastfeeding women.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

10 participants in 2 patient groups, including a placebo group

Aripiprazole
Experimental group
Description:
Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
Treatment:
Drug: Aripiprazole
Sugar pill
Placebo Comparator group
Description:
placebo arm,5mg/pill,10mg/day,last12weeks
Treatment:
Drug: placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems